On Air Now

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 1450 AM Holland, MI

Weather

Current Conditions(Holland,MI 49422)

More Weather »
60° Feels Like: 60°
Wind: SW 10 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 59°

Tomorrow

Thunderstorms 73°

Sun Night

Thunderstorms 60°

Alerts

Pfizer kidney cancer drug fails as initial treatment

The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen
The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen

(Reuters) - Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.

The trial was testing the drug Inlyta in patients who have received no prior treatments and compared its effects with another kidney cancer drug, sorafenib. Inlyta is already approved to treat kidney cancer that has not responded to prior therapy.

Sorafenib is marketed as Nexavar by Onyx Pharmaceuticals Inc and Germany's Bayer AG. (Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)

Comments